Insight Molecular Diagnostics Inc.
NASDAQ:IMDXMedical - Diagnostics & Research
+$0.13 today
- Market cap
- $52.08M
- Beta
- 1.79
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.39
Volume 0.64M
Average 0.38M
IMDX EBITDA Margin
EBITDA as a percentage of revenue.
Insight Molecular Diagnostics Inc.NASDAQ: IMDX
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin narrows to -11362.5%
EBITDA Margin was -11362.5% in Q1 FY2026, down 11074.8 pp from a year earlier. On a trailing-twelve-month basis it was -2329.5%, down 862.2 pp year over year. Over 3 fiscal years it widened by 207.6 pp.
Context
- EBITDA Margin widened in 1 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 5 analysts of -1611.6% for the fiscal year ending Dec 2026, down from -1181.7% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -11362.5%-9398.8 pp QoQ
- Last fiscal yearDec 2025
- -1181.7%+1955.8 pp YoY
- LTMMar 2026
- -2329.5%-862.2 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -1181.7%
- Year-over-year change
- +1955.8pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -1181.7% | +1955.8pp |
| FY2024 | 2024-12-31 | -3137.4% | -1599.0pp |
| FY2023 | 2023-12-31 | -1538.5% | -149.2pp |
| FY2022 | 2022-12-31 | -1389.2% | +815.3pp |
| FY2021 | 2021-12-31 | -2204.6% | — |
EBITDA Margin vs competitors
How IMDX compares with its peers on the latest reported figures
- IMDX's LTM Mar 2026 EBITDA Margin of -2329.5% is the 7th highest of the 9 companies compared; the peer median is -313.9%.
- Its year-over-year change of -862.2 pp is the 7th highest of 8, against a peer median of +50.4 pp.
- Over three fiscal years its change of +207.6 pp compares with a peer median of -178.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -28.2% | +91.2 pp | -29.1 pp | |
| LTM Mar 2026 | -117.0% | +50.4 pp | -225.4 pp | |
| LTM Mar 2026 | -135.5% | +244.4 pp | — | |
| LTM Mar 2026 | -287.9% | -44.6 pp | +113.4 pp | |
| LTM Mar 2026 | -339.9% | -229.0 pp | -131.5 pp | |
| LTM Mar 2026 | -455.3% | +1345.3 pp | — | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | -2329.5% | -862.2 pp | +207.6 pp |
| LTM Mar 2026 | -3439.7% | — | -2679.5 pp | |
| LTM Mar 2026 | -8872.8% | -9159.7 pp | -2521.0 pp | |
| FY2025 | — | — | — | |
| Peer median (excluding IMDX) | -313.9% | +50.4 pp | -178.5 pp | |
Competitors are the stored peer set for IMDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.2M | 958K | 1.5M | 1.88M | 4.06M |
| Cost of Revenue | 778K | 976K | 1.09M | 1.14M | 3.87M |
| Gross Profit | 1.42M | (18K) | 413K | 740K | 190K |
| Gross Margin | 64.6% | -1.9% | 27.5% | 39.3% | 4.7% |
| Research & Development | 5.04M | 7.3M | 9.29M | 9.84M | 15.9M |
| Selling, General & Admin | 20.39M | 21.53M | 13.29M | 13.79M | 16.98M |
| Operating Expenses | 55.15M | 17.98M | 25.55M | 61.78M | 30.77M |
| Depreciation & Amortization | 4.21M | 5.22M | 1.68M | 1.56M | 2.2M |
| EBITDA | (48.46M) | (13.31M) | (23.12M) | (59.02M) | (47.92M) |
| EBITDA Margin | -2204.6% | -1389.2% | -1538.5% | -3137.4% | -1181.7% |
| Operating Income | (53.73M) | (18M) | (25.14M) | (61.04M) | (30.58M) |
| Operating Margin | -2444.3% | -1878.6% | -1672.4% | -3245.1% | -754.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 209K | 83K | 52K | 84K | 109K |
| Other Income / Expenses | 854K | (615K) | 281K | 378K | (19.64M) |
| Income Before Tax | (52.87M) | (18.61M) | (24.86M) | (60.66M) | (50.22M) |
| Pre-Tax Margin | -2405.4% | -1942.8% | -1653.7% | -3225.0% | -1238.5% |
| Income Tax Expense | (9.26M) | 0 | 0 | 0 | 0 |
| Net Income | (64.1M) | (72.9M) | (27.78M) | (60.66M) | (50.22M) |
| Net Margin | -2916.2% | -7609.8% | -1848.4% | -3225.0% | -1238.5% |
| EPS (Basic) | (14.40) | (20.00) | (3.75) | (4.66) | (1.65) |
| EPS (Diluted) | (14.40) | (20.00) | (3.75) | (4.66) | (1.65) |
| Weighted Avg Shares | 4.45M | 5.54M | 7.65M | 13.07M | 30.48M |
| Weighted Avg Shares (Diluted) | 4.45M | 5.54M | 7.65M | 13.07M | 30.48M |
Insight Molecular Diagnostics Inc.
NASDAQ:IMDX
Intrinsic Alpha fair value
Locked
Current Price
$1.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.